Navigation Links
Researchers Spot Potential Bile Duct Cancer Drug Targets
Date:1/26/2012

THURSDAY, Jan. 26 (HealthDay News) -- Researchers who identified a new genetic signature associated with bile duct cancer say their discovery could lead to targeted treatment for the deadly cancer.

The team at the Massachusetts General Hospital Cancer Center screened samples from 287 patients with gastrointestinal tumors and found that growth-enhancing mutations in two genes (IDH1 and IDH2) may account for nearly one-fourth of bile duct tumors that develop in the liver.

Mutations in IDH1 were found in 13 percent of all bile duct tumors and in 23 percent of those within the liver itself. Mutations in IDH2 were less common.

It may be possible to develop drugs that target this mutation in order to control tumor growth, they said.

The findings were published online in The Oncologist.

Bile duct cancer occurs in a duct that carries bile from the liver to the small intestine.

"Patients with bile duct cancer have a generally poor prognosis. Most of them are diagnosed with advanced or metastatic disease, so surgical resection [removal] is not feasible," study co-senior author Dr. Andrew Zhu, director of Liver Cancer Research at the MGH Cancer Center, said in a hospital news release.

"Identifying this new and relatively common mutation in intrahepatic [within the liver] bile duct cancer may have significant implications for the diagnosis, prognosis and therapy of patients whose tumors harbor this mutation," Zhu added.

Currently, there are no drugs that target IDH mutations, but extensive efforts are underway to develop such drugs, the researchers say.

Each year in the United States, 12,000 people are diagnosed with cancers of the gallbladder and bile duct, but only 10 percent of those cancers are discovered early enough for successful surgical treatment. Average survival, even with chemotherapy, is less than a year.

More information

The American Cancer Society has more about bile duct cancer.

-- Robert Preidt

SOURCE: Massachusetts General Hospital, news release, Jan. 18, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Georgetown Lombardi researchers present new findings on head & neck cancers
2. Researchers discover method to unravel malarias genetic secrets
3. Researchers quantify muscle soreness
4. Georgetown professor applauds decision of researchers to temporarily halt research on H5N1
5. Health benefits of exercise may depend on cellular degradation, UT Southwestern researchers report
6. Autism redefined: Yale researchers study impact of proposed diagnostic criteria
7. University of Tennessee researchers develop comprehensive, accessible vision testing device
8. Lawson researchers engineer a switch to tame aggressive cancers
9. UC Davis researchers refine nanoparticles for more accurate delivery of cancer drugs
10. Researchers study how chemicals in drugs and around us impact stem cells
11. University of Granada researchers identify changes in tumor cells that lead to metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers Spot Potential Bile Duct Cancer Drug Targets 
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who ... now take advantage of a cosmetic procedure known as Carbon Dioxide (C02) ... the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Halfway through ... Medicine has provided preventative dental services to more than 15,900 children 5 years old ... 5 LA pledged $38 million over a span of five years to Western University ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
(Date:12/2/2016)... ... ... Advanced Inc., a leading provider of travel therapy and travel nursing across ... Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as Vice ... leadership experience to Advanced Inc. He began his career in finance at Ernst & ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... Dec. 3, 2016 Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... , , ...
(Date:12/4/2016)... highly innovative, personalized cell-based treatment for a high-risk form of the most ... Children,s Hospital of Philadelphia today reported new results ... The physician-scientists presented findings at the annual meeting of the ... Continue Reading ... ...
(Date:12/2/2016)... -- bioLytical Laboratories, un líder mundial en test rápidos de enfermedades ... Test , a los miembros de la Kenya Pharmaceutical Association. ... ... HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton Health ...
Breaking Medicine Technology: